Hydroxamate based inhibitors of adenylyl cyclase. Part 1: The effect of acyclic linkers on P-site binding

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 21, 2002, Pages 3085-3088

  Levy, Daniel E ^a   Marlowe, Charles ^a   Kane Maguire, Kim ^a   Bao, Ming ^a   Cherbavaz, Diana B ^a   Tomlinson, James E ^a   Sedlock, David M ^a   Scarborough, Robert M ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID; ADENINE; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; CYCLIC AMP; ENZYME; ENZYME INHIBITOR; HYDROXAMIC ACID DERIVATIVE; LINK PROTEIN; METAL ION; NUCLEOTIDE; PURINE; PYROPHOSPHATE;

ANALYSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CATALYSIS; CONTROLLED STUDY; CRYSTALLOGRAPHY; CYCLIZATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME STRUCTURE; HUMAN; HUMAN CELL; METAL BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

ADENYLATE CYCLASE; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; HYDROGEN BONDING; HYDROXAMIC ACIDS; INDICATORS AND REAGENTS; ISOENZYMES; KIDNEY; MAGNESIUM; PROTEIN CONFORMATION; RECEPTORS, PURINERGIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037020761     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00653-4     Document Type: Article

References (20)

1. Toya Y., Schwencke C., Ishikawa Y. J. Mol. Cell. Cardiol. 30:1998;97.
2. Hellevuo K., Hoffman P.L., Tabakoff B. J. Neurochem. 67:1996;177.
3. Goldstein J., Silberstein C., Ibarra C. Braz. J. Med. Biol. Res. 35:2002;145.
4. Braunwald, E.; Zipes, D. P.; Libby, P. In Heart Disease, 6th ed.; W. B. Saunders Company; Philadelphia, 1997.
5. Hamm H.E. J. Biol. Chem. 273:1998;669.
6. Taussig R., Gilman A.G. J. Biol. Chem. 270:1995;1.
7. Ishikawa Y., Homcy C. J. Circ. Res. 80:1997;297.
8. Susanni, E. E.; Vatner, D. E.; Homcy, C. J. In The Heart and Cardiovascular System, 2nd Ed., Fozzard, H. A., Ed.; Raven Press, Ltd.: New York, 1992.
9. Johnson R.A., Shoshani I. J. Biol. Chem. 265:1990;19035.
10. Kleinman E.F., Campbell E., Giordano L.A., Cohan V.L., Jenkinson T.H., Cheng J.B., Shirley J.T., Pettipher E.R., Salter E.D., Hibbs T.A., DiCapua F.M., Bordner J. J. Med. Chem. 41:1998;266.
11. Dessauer C.W., Tesmer J.J.G., Sprang S.R., Gilman A.G. Trends Pharmacol. Sci. 20:1999;205.
12. Tesmer J.J.G., Sunahara R.K., Johnson R.A., Gosselin G., Gilman A.G., Sprang S.R. Science. 285:1999;756.
13. Howarth N.M., Wakelin L.P.G. J. Org. Chem. 62:1997;5441.
14. Ciapettii P., Soccolini F., Taddei M. Tetrahedron. 53:1997;1167.
15. Levy D.E., Lapierre F., Liang W., Ye W., Lange C.W., Li X., Grobelny D., Casabonne M., Tyrrell D., Holme K., Nadzan A., Galardy R.E. J. Med. Chem. 41:1998;199.
16. Paulissen R., Reimlinger H., Hayez E., Hubert A.J., Teyessie Ph. Tetrahedron Lett. 14, 1973;. 2233.
17. Wang J., Herdewijn P. J. Org. Chem. 64:1999;7820.
18. Lowe G., Vilaivan T. J. Chem. Soc., Perkin Trans. 1. 1997;539.
19. Villemin D., Thibault-Starzyk F. Synth. Commun. 23:1993;1053.
20. 2. Compounds were added to the mixture and the reaction was run for 30 min at 30°C. Terminated reactions were evaluated for the enzymatic product, cAMP, using a commercially available New England Nuclear flash plate system. The degree of inhibition was determined by comparing the measured cAMP concentrations to those measured in control reactions containing no compound.